The clinical trial identified by NCT05973773, known as REZILIENT3, is a phase 3 global, multicenter study evaluating the combination of zipalertinib and chemotherapy as a potential first-line treatment for adult patients with previously untreated, locally advanced or metastatic non-squamous NSCLC that have EGFR exon 20 insertion mutations. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.